#ASCO19: Clay Siegall is ready to take a big leap forward as Seattle Genetics’ next top drug prospect steps onto center stage at ASCO
CHICAGO — Clay Siegall is coming up to a finish line he’s been walking, running and crawling toward — in stages, as required — for the past 21 years, ever since he founded Seattle Genetics.
This morning he revealed more about the pivotal-stage antibody drug conjugate he and Aya Jakobovits put together when she was CSO at Agensys. Now partnered with Astellas, which bought out the biotech in 2007 and stepped into the shoes of a 50-50 partnership, his company is steering into what could shape up as a quick review for a drug bound for patients with no approved options left — with a breakthrough drug designation to its credit to help keep things on the fast track at an FDA that has become expert at this.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.